ArticleNature communications2025
Slc22a17 governs postnatal neurogenesis by maintaining the iron homeostasis in hippocampus.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Amyloid Precursor Protein Abnormalities Destabilize Membrane Ferroportin: A Novel Mechanism Underlying Early Brain Pathologies and Memory Impairment in Alzheimer's Disease.International journal of molecular sciences · 2026Article
- From scavenger to victim: mechanism and treatment of microglial ferroptosis in white matter injury disease.Frontiers in immunology · 2026Review
- Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Iron transporters are essential for numerous iron-dependent biological processes. Among them, SLC22A17 plays a key role in lipocalin-2 (LCN2)-mediated iron transport and is implicated in several human diseases. However, its precise molecular and physiological functions remain poorly understood. In this study, we demonstrate that Slc22a17 is critical for postnatal neurogenesis through its regulation of iron homeostasis in the hippocampus. Conditional knockout of Slc22a17 in the murine brain results in early postnatal mortality, severe growth retardation, excessive neural stem cell (NSC) apoptosis, and cognitive impairments, all driven by oxidative stress caused by iron overload. Mechanistically, using TurboID-based proximity labeling and immunoprecipitation, we identify an interaction between Slc22a17 and p62, which modulates Nrf2 activity. Loss of Slc22a17 activates the Nrf2/HO-1 pathway, paradoxically enhancing iron release while impairing iron efflux. This imbalance triggers the production of iron-catalyzed reactive oxygen species (ROS), leading to oxidative stress. Together, our findings highlight Slc22a17 as a potential therapeutic target for neurological disorders associated with iron dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.